

## Prescription Opioid Addiction Treatment Study (POATS) Blending Initiative Product Resource List

### Peer-Reviewed Journal Articles

Albright, J., Ciaverelli, R., Essex, A., Tkacz, J., Ruetsch. (2010). Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. *Journal of Addiction Medicine*, 4(4), 197-203.

Alford, D.P., LaBelle, C.T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J.H. (2011). Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience. *Archives of Internal Medicine*, 17(5), 425-31.

Barnett, P., Rodgers, J. & Bloch, D. (2001). A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. *Addiction*, 96, 683-90.

Bohnert, A.S.B., Valenstein, M., Bair, M.J., Ganoczy, D., McCarthy, J.F., Ilgen, M.A., & Blow, F.C. (2011). Association between opioid prescribing patterns and opioid overdose-related deaths. *Journal of the American Medical Association*, 305(13), 1315-21.

Bryson, W.C., McConnell, K.J., Korthuis, P.T., & McCarty, D. (2011). Extended-release naltrexone for alcohol dependence: Persistence and healthcare costs and utilization. *The American Journal of Managed Care*, 17(8), S213-22.

Burns, L., Randall, D., Hall, W., Butler, T., Bell, J., and Degenhardt, L. (2009). Opioid agonist pharmacotherapy in new South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention. *Journal of Addiction*, 104, 1363-72.

Comer, S.D., Sullivan, M.A., Vosburg, S.K., Manubay, J., Amass, L., Cooper, Z.D., Saccone, P., and Kleber, H.D. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. *Journal of Addiction*, 105, 709-18.

Comer, S.D., Walker, E.A., & Collins, E.D. (2005). Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. *Journal of Psychopharmacology*, 181, 664-75.

Cornish, R., Macleod, J., Strang, J., Vickerman, P., & Hickman, M. (2010). Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK General Practice Research Database. *British Medical Journal*, 34, 1-8.

### **Peer-Reviewed Journal Articles, continued**

- Cunningham, C., Giovanniello, A., Sacajiu, G., Whitley, S., Mund, P., Beil, R., & Sohler, N. (2008). Buprenorphine treatment in an urban community health center: What to expect. *Journal of Family Medicine, 40*(7), 500-06.
- Damschroder, L.J., Aron, D.C., Keith, R.E., Kirsh, S.R., Alexander, J.A., and Lowery, J.C. (2009). Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implementation Science, 4*, 50.
- Damschroder, L.J., & Hagedorn, H.J. (2011). A guiding framework and approach for implementation research in substance use disorders treatment. *Psychology of Addictive Behaviors, 25*(2), 194-205.
- Degenhardt, L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M., & McLaren, J. (2010). Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies. *Journal of Addiction, 106*, 32-51.
- Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacology program over 20 years: Risk factors and lives saved. *Journal of Drug and Alcohol Dependence, 105*, 9-15.
- Denisco, R.C., Kenna, G.A., O'Neil, M.G., Kulich, R.J., Moore, P.A., Kane, W.T., Mehta, N.R., Hersh, E.V., & Katz, N.P. (2011). Prevention of prescription opioid abuse: The role of the dentist. *Journal of the American Dental Association, 142*(7), 800-10.
- Ducharme, L.J., & Abraham, A.J. (2008). State policy influence on the early diffusion of buprenorphine in community treatment programs. *Journal of Substance Abuse Treatment, Prevention, and Policy, 3*(17), 1-10.
- Ducharme, L.J., Knudsen, H.K., & Roman, P.M. (2006). Evidenced-based treatment for opiate-dependent clients: Availability, variation, and organizational correlates. *The American Journal of Drug and Alcohol Abuse, 32*, 696-576.
- Ducharme, L.J., & Roman, P.M. (2009). Opioid treatment programs in the Clinical Trials Network: Representiveness and buprenorphine adoption. *Journal of Substance Abuse Treatment, 37*, 90-4.
- Egan, J.E., Casadonte, P., Gartenmann, T., Martin, J., McCance-Katz, E.F., Netherland, J., Renner, J.A., Weiss, L., Saxon, A.J., & Fiellin, D.A. (2010). The Physician Clinical Support System-Buprenorphine (PCSS-B): A novel project to expand/improve buprenorphine treatment. *Journal of General Internal Medicine, 25*(9), 936-41.

### **Peer-Reviewed Journal Articles, continued**

- Fiellin, D.A., Moore, B.A., Sullivan, L.E., Becker, W., pantaloon, M.V., Chawarski, M.C., Barry, D., T., O'Connor, P., Schottenfeld, R.S. (2008). Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. *The American Journal on Addictions, 17*, 116-20.
- Fiellin, D.A., Pantalon, M.V., Chawarski, M.C., Moore, B.A., Sullivan, L.E., O'Connor, P.G., & Schottenfield, R.S. (2006). Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. *New England Journal of Medicine, 355*, 365-74.
- Johnson, R.E., Fudula, P.J., & Payne, R. (2005). Buprenorphine: Considerations for pain management. *Journal of Pain and Symptom Management, 29*(3), 297-326.
- Kahan, M., Srivastava, A., Ordean, A., Cirone, S. (2011). Buprenorphine: New treatment of opioid addiction in primary care. *Journal of Canadian Family Medicine, 57*, 281-89.
- Knudsen, H.K., Abraham, A.J., Johnson, J.A., & Roman, P.M. (2009). Buprenorphine adoption in the national drug abuse treatment Clinical Trials Network. *Journal of Substance Abuse Treatment, 37*, 307-12.
- Knudsen, H.K., Ducharme, L.J., Roman, P.M., & Link, T. (2005). Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. *Journal of Substance Abuse Treatment, 29*, 95-106.
- Ling, W., Jacobs, P., Hillhouse, M., Hasson, A., Thomas, C., Freese, T., Sparenborg, S., McCarty, D., Weiss, R., Saxon, A., Cohen, A., Straus, M., Brigham, G., Liu, D., McLaughlin, P., Tai, B. (2010). From research to real world: Buprenorphine in the decade of the Clinical Trials Network. *Journal of Substance Abuse Treatment, 38*, S53-60.
- Magura, S., & Rosenblum, A. (2001). Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored. *Mount Sinai Journal of Medicine, 68*(1), 62-74.
- Marchand, K., Oviedo-Joekes, E., Guh, D., Brissette, S., Marsh, D., and Schechter, M.T. (2011). Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency. *BMC Health Services, 11*, 174.
- Mark, T.L., Kranzler, H.R., Song, X. (2003). Understanding U.S. addiction physicians' low rate of naltrexone prescription. *Journal of Drug and Alcohol Dependence, 71*, 219-28.

### **Peer-Reviewed Journal Articles, continued**

Mark, T.L., Montejano, L.B., Kranzler, H.R., Chalk, M., & Gastfriend, D.R. (2010). Comparison of healthcare utilization among patients treated with alcoholism medications. *The American Journal of Managed Care*, 16(12), 879-88.

Martino, S., Brigham, G.S., Higgins, C., Gallon, S., Freese, T.E., Albright, L.M., Hulse, E.G., Krom, L., Storti, S.A., Peri, H., Nugent, C.D., Pintello, D., Condon, T.P. Partnerships and pathways of dissemination: The national institute on drug abuse—Substance abuse and mental health services administrations blending initiative in the Clinical Trials Network. *Journal of Substance Abuse Treatment*, 36(1), 31-43.

Mendelson, J., Flower, K., Pletcher, M.J., & Galloway, G.P. (2008). Addiction to prescription opioids: Characteristics of the emerging epidemic and treatment with buprenorphine. *Journal of Experimental and Clinical Psychopharmacology*, 16(5), 435-41.

Moore, B.A., Fiellin, D.A., Barry, D.T., Sullivan, L.E., Chawarski, M.C., O'Connor, P.G., & Schottenfeld, R.S. (2007). Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. *Society of General Internal Medicine*, 22, 527-30.

Netherland, J., Botsko, M., Egan, J.E., Saxon, A.J., Cunningham, C.O., Finkelstein, R., Gourevitch, M.N., Renner, J.A., Sohler, N., Sullivan, L.E., Weiss, L., & Fiellin, D.A. (2009). Factors affecting willingness to provide buprenorphine treatment. *Journal of Substance Abuse Treatment*, 36(3), 244-51.

Price, A.M., Ilgen, M.A., & Bohnert, A.S.B. (2011). Prevalence and correlates of nonmedical use of prescription opioids in patients seen in a residential drug and alcohol treatment program. *Journal of Substance Abuse Treatment*, 41(2), 208-14.

Reynaud, M., Petit, G., Potard, D., & Courty, P. (1998). Six deaths linked to concomitant use of buprenorphine and benzodiazepines. *Addiction*, 93(9), 1385-92.

Rieckmann, T., Kovas, A.E., & Rutkowski, B.A. (2010). Adoption of medications in substance abuse treatment: Priorities and strategies of single state authorities. *Journal of Psychoactive Drugs, SARC Supplement 6*, 227-38.

Rieckmann, T., Daley, M., Fuller, B.E., Thomas, C.P., and McCarty, D. (2007). Client and counselor attitudes toward the use of medications for treatment of opioid dependence. *Journal of Substance Abuse Treatment*, 32(2), 207-15.

Roman, P.M., & Johnson, J.A. (2002). Adoption and implementation of new technologies in substance abuse treatment. *Journal of Substance Abuse Treatment*, 22, 211-18.

### **Peer-Reviewed Journal Articles, continued**

- Strassels, S.A. (2009). Economic burden of prescription opioid misuse and abuse. *Journal of Managed Care Pharmacy, 15*(7), 556-62.
- Sullivan, L.E., Barry, D., Moore, B.A., Chawarski, M.C., Tetrault, J.M., Pantaloni, M.V., O'Connor, P.G., Schottenfeld, R.S., Fiellin, D. (2006). A trial of integrated buprenorphine/naloxone and HIV clinical care. *Journal of Clinical Infectious Diseases, 43*, 184-90.
- Tai, B., Straus, M.M., Liu, D., Sparenborg, S., Jackson, R., & McCarty, D. (2010). The first decade of the National Drug Abuse Treatment clinical Trials Network: Bridging the gap between research and practice to improve drug abuse treatment. *Journal of Substance Abuse Treatment, 38*(1), 4-13.
- Thomas, C.P., Reif, S., Haq, S., Wallack, S.S., Hoyt, A., & Ritter, G.A. (2008). Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. *Journal of Psychiatric Services, 59*(8), 909-16.
- Upadhyay, J., Maleki, N., Potter, J., Elman, I., Rudrauf, D., Knudsen, J., Wallin, D., Pendse, G., McDonald, L., Griffin, M., Anderson, J., Nutile, L., Renshaw, P., Weiss, R., Becerra, L., & Borsook, D. (2010). Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. *Brain, 133*, 2098-114.
- Wallack, S.S., Thomas, C.P., Martin, T.C., Chilingirian, & Reif, S. (2010). Substance abuse treatment organization as mediators of social policy slowing the adoption of a congressionally approved medication. *Journal of Behavioral Health Services and Research, 37*(1), 65-78.
- Weiss, R.D., Sharpe Potter, J., Fiellin, D.A., Byrne, M., Connery, H.S., Dickinson, W., Gardin, J., Griffin, M.L., Gourvetich, M.N., Haller, D.L., Hasson, A.L., Huang, Z., Jacobs, P., Kosinski, A.S., Lindblad, R., McCance-Katz, E.F., Provost, S.E., Selzer, J., Somoza, E.C., Sonne, S.C., & Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry, 68*(12), 1238-46.
- Weiss, R.D., Sharpe Potter, J., Provost, S.E., Huang, Z., Jacobs, P., Hasson, A., Lindblad, R., Smith Connery, H., Prather, K., & Ling, W. (2010). A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): Rationale, design, and methodology. *Contemporary Clinical Trials, 31*(2), 189-99.
- West, J.C., Thomas, R., Kosten, M.D., Wilk, J., Svikis, D., Triffleman, E., Rae, D.S., Narrow, W.E., Duffy, F.F., & Regier, D.A. (2004). Challenges in increasing access to buprenorphine treatment for opiate addiction. *The American Journal on Addictions, 13*(1), 8-16.

### **Peer-Reviewed Journal Articles, continued**

- Wu, L-T., Pilowsky, D.J., & Patkar, A.A. (2008). Non-prescribed use of pain relievers among adolescents in the United States. *Journal of Drug and Alcohol Dependence, 94*, 1-11.
- Wu, L-T., Rignwalt, C.L., Yang, C., Reeve, B.B., Pan, J-J., & Blazer, D.G. (2009). Construct and differential item functioning in the assessment of prescription opioid use disorders among American adolescents. *Journal of the American Academy of Child and Adolescent Psychiatry, 48*(5), 563-72.
- Wu, L-T., Ling, W., Burchett, B., Blazer, D.G., Yang, C., Pan, J-J., Reeve, B.B., & Woody, G.E. (2011). Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network. *Journal of Drug and Alcohol Dependence*. [ARTICLE IN PRESS]
- Wu, L-T., Woody, G.E., Yang, C., & Blazer, D.G. (2011). How do prescription opioid users differ from users of heroin or other drugs in psychopathology: Results from the national epidemiologic survey on alcohol and related conditions. *Journal of Addiction Medicine, 5*(1), 28-35.
- Wu, L-T., Woody, G.E., Yang, C., & Blazer, D.G. (2010). Subtypes of nonmedical opioid users: Results from the national epidemiologic survey on alcohol and related conditions. *Journal of Drug and Alcohol Dependence, 112*, 69-80.
- Wu, L-T., Woody, G.E., Yang, C., Mannelli, P., & Blazer, D.G. (2011). Differences in onset and abuse/dependence between prescription opioids and heroin: Results from the national epidemiologic survey on alcohol and related conditions. *Journal of Substance Abuse and Rehabilitation, 2*, 77-88.
- Wu, L-T., Woody, G.E., Yang, C., Pan, J-J., & Blazer, D.G. (2011). Abuse and dependence on prescription opioids in adults: A mixture categorical and dimensional approach to diagnostic classification. *Journal of Psychological Medicine, 41*, 653-64.

### **Research Reports, Treatment Manuals, and Ancillary Materials**

- Center for Substance Abuse Treatment. (2005). *Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs, Treatment Improvement Protocol (TIP) Series 43*, DHHS Publication No. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration, retrieved from <http://www.ncbi.nlm.nih.gov/books/NBK14677/>.

### **Research Reports, Treatment Manuals, and Ancillary Materials, continued**

Center for Substance Abuse Treatment. (2004). *Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, Treatment Improvement Protocol (TIP) Series 40*, DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, retrieved from [http://buprenorphine.samhsa.gov/Bup\\_Guidelines.pdf](http://buprenorphine.samhsa.gov/Bup_Guidelines.pdf).

Fiellin, D.A., Pantalon, M.V., Schottenfeld, R.S., Gordon, L., & O'Connor, P.G. (1999). *Manual for Standard Medical Management of Opioid Dependence with Buprenorphine*. West Haven, CT: Yale University School of Medicine, Primary Care Center and Substance Abuse Center, and West Haven VA/CT Healthcare System.

Institute of Medicine of the National Academies. (2011). *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research*. Washington, D.C.: Author.

Ling, W., & Obert, J. (n.d.). *Handbook for Recovery from Opiate Dependence*. Bethesda, MD: National Institute on Drug Abuse, Center for Clinical Trials Network.

National Association on Alcohol Abuse and Alcoholism (NIAAA). (2007). *Helping Patients Who Drink Too Much: A Clinician's Guide*. NIH Publication No. 07-3769. Bethesda, MD: U.S. Department of Health and Human Sciences, National Institute on Alcohol Abuse and Alcoholism.

World Health Organization. (2009). *Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence*. Geneva, Switzerland: Author.

### **Technical Reports, Fact Sheets, and Additional Data Sources**

Centers for Disease Control and Prevention. (2002). IDU/HIV Prevention: Substance Abuse Treatment for Injection Drug Users – A Strategy with Many Benefits. Atlanta, GA: Author, retrieved from <http://www.cdc.gov/idu/facts/TreatmentFin.pdf>.

Centers for Disease Control and Prevention, National Center for HIV, STD and TB Prevention. (2000). *Methadone Maintenance Treatment*. Atlanta, GA: Author, retrieved from [www.cdc.gov/idu/facts/MethadoneFin.pdf](http://www.cdc.gov/idu/facts/MethadoneFin.pdf).

CESAR (2011a). Buprenorphine Treatment for Opioid Dependence. *Volume 20, Issue 22*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-22.pdf>.

CESAR (2011b). U.S. Retail Distribution of Buprenorphine Approaches 1.5 Million Grams. *Volume 20, Issue 23*. Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-23.pdf>.

### **Technical Reports, Fact Sheets, and Additional Data Sources, continued**

CESAR (2011c). Number of Law Enforcement-Seized Buprenorphine Items Analyzed by U.S. Labs Increases Dramatically. *Volume 20, Issue 24*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-24.pdf>.

CESAR (2011d). Number of U.S. Emergency Department Visits Related to the Nonmedical Use of Buprenorphine More than Triples since 2006. *Volume 20, Issue 25*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-25.pdf>.

CESAR (2011e). Sixty-One Percent (61%) of Buprenorphine-Related Emergency Department Visits for Nonmedical Use. *Volume 20, Issue 26*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-26.pdf>.

CESAR (2011f). Buprenorphine Availability, Diversion, and Misuse: A Summary of the CESAR Fax Series. *Volume 20, Issue 34*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-34.pdf>.

CESAR (2011g). Clinical Trial Finds that While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use among Those Dependent on Prescription Opioids, 91% were Not Opioid Free at Follow-Up. *Volume 20, Issue 46*, Center for Substance Abuse Research, University of Maryland, College Park, retrieved from <http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-46.pdf>.

Substance Abuse and Mental Health Services Administration. (2001). *Federal Register: 42 CFR Part 8, Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction, Final Rule*. Rockville, MD: U.S. Department of Health and Human Services, retrieved from <http://dpt.samhsa.gov/pdf/regs.pdf>.

Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. (2009). Emerging Issues in the Use of Methadone, HHS Publication No. (SMA) 09-4368. *Substance Abuse Treatment Advisory, Volume 8, Issue 1*. Rockville, MD: U.S. Department of Health and Human Services, retrieved from <http://kap.samhsa.gov/products/manuals/advisory/pdfs/Methadone-Advisory.pdf>.

Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, Division of Pharmacologic Therapies. (2007). *Summary Report of the Meeting: Methadone Mortality – A Reassessment*. Rockville, MD: U.S. Department of Health and Human Services, retrieved from [http://dpt.samhsa.gov/pdf/Methadone\\_Report\\_10%2018%2007\\_Brief%20w%20attch.pdf](http://dpt.samhsa.gov/pdf/Methadone_Report_10%2018%2007_Brief%20w%20attch.pdf).



### **Technical Reports, Fact Sheets, and Additional Data Sources, continued**

Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, Division of Pharmacologic Therapies. (n.d.). *Accreditation of Methadone Maintenance Treatment: Assuring Quality of Care*, retrieved from <http://dpt.samhsa.gov/pdf/001218accred.pdf>.

Vimont, C. (2011). Challenges of treating chronic pain in people with opioid dependence. Join Together Online, retrieved from, <http://www.drugfree.org/join-together/addiction/challenges-of-treating-chronic-pain-in-people-with-opioid-dependence> (June 24, 2011).

### **Websites**

Addiction Technology Transfer Center Network: <http://www.attcnetwork.org>

Alliance of States with Prescription Monitoring Programs: <http://www.pmpalliance.org>

Buprenorphine Physician and Treatment Program Locator:  
[http://buprenorphine.samhsa.gov/bwns\\_locator/](http://buprenorphine.samhsa.gov/bwns_locator/)

How to Use Methadone Safely Campaign: <http://dpt.samhsa.gov/methadonesafety/index.aspx>

NIDA/SAMHSA Blending Initiative Website: [www.nida.nih.gov/blending](http://www.nida.nih.gov/blending)

PMP Center of Excellence, Brandeis University, Schneider Institutes for Health Policy:  
<http://www.pmpexcellence.org>

SAMHSA-CSAT's Medication Assisted Treatment for Substance Use Disorders, Division of Pharmacologic Therapies: <http://dpt.samhsa.gov/medications/methadone.aspx>

SAMHSA-CSAT's Medication Assisted Treatment for Substance Use Disorders, Division of Pharmacologic Therapies, Opioid Treatment Program Accreditation:  
<http://dpt.samhsa.gov/regulations/accreditation.aspx>

Opioid addiction treatment can be a long-term process, but medications and counseling can improve your chances of success. Learn more about all the different measures to treat opioid addiction. Prescription drug addiction alters the circuits that handle mood and reward behavior. In addition, long-term prescription drug abuse affects almost all of your body's systems. When you cut off the opioid supply, you're likely to get withdrawal symptoms such as

If you have an opioid (also called a narcotic) addiction, you know that a list of these symptoms doesn't capture the agony of going through them. It's very unpleasant, and you do almost anything to avoid it. Opioid withdrawal lasts hours to days -- and sometimes weeks.

an Adaptive Treatment Research Design in a CTN study of prescription opioid dependence treatment RD Weiss 1,2, JS Potter 2,3, M Byrne 4, C Sullivan 4, W Ling 5 1. McLean Hospital, Belmont, MA, USA 2.Department of Psychiatry, Harvard Medical School, Boston, MA, USA 3.University of Texas Health Science Center, San Antonio, TX, USA 4.West Virginia University School.

Conclusions: ATRD, applied to the POATS study, presents an opportunity to evaluate a treatment strategy rather than a discrete intervention. This research design has advantages and challenges that researchers need to consider in both the design and implementation stages of a clinical trial.

Background: The multi-site Prescription Opioid Addiction Treatment Study (POATS), conducted by the National Drug Abuse Treatment Clinical Trials Network, was the largest clinical trial yet conducted with patients dependent upon prescription opioids (N=653). In addition to main trial results, the study yielded numerous secondary analyses, and included a 3.5-year follow-up study, the first of its kind with this population. This paper reviews key findings from POATS and its follow-up study.

Methods: The paper summarizes the POATS design, main outcomes, predictors of outcome, subgroup analyses, th

Short Description. Download Prescription Opioid Addiction Treatment Study (POATS) Description. View more